The role of IL-13 in established allergic airway disease

Christian Taube, Catherine Duez, Zhi Hua Cui, Katsuyuki Takeda, Yeong Ho Rha, Jungwon Park, Annette Balhorn, Debra D. Donaldson, Azzeddine Dakhama, Erwin W. Gelfand

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

The effectiveness of targeting IL-13 in models where airway hyperresponsiveness (AHR) and airway inflammation have already been established is not well-described. We investigated the effects of blocking IL-13 on the early and late phase airway responses and the development of AHR in previously sensitized and challenged mice. BALB/cByJ mice were sensitized (days 1 and 14) and challenged (days 28-30) with OVA. Six weeks later (day 72), previously sensitized/challenged mice were challenged with a single OVA aerosol and the early and late phase response and development of AHR were determined. Specific in vivo blockade of IL-13 was attained after i.p. injection of a soluble IL-13Rα2-IgG fusion protein (sIL-13Rα2Fc) on days 71-72 for the early and late responses and on days 71-73 for the development of AHR. sIL-13Rα2Fc administration inhibited the late, but not early, phase response and the OVA challenge-induced changes in lung resistance and dynamic compliance; as well, sIL-13Rα2Fc administration decreased bronchoalveolar lavage eosinophilia and mucus hypersecretion following the secondary challenge protocols. These results demonstrate that targeting IL-13 alone regulates airway responses when administrated to mice with established allergic airway disease. These data identify the importance of IL-13 in the development of allergen-induced altered airway responsiveness following airway challenge, even when administered before rechallenge of mice in which allergic disease had been previously established.

Original languageEnglish
Pages (from-to)6482-6489
Number of pages8
JournalJournal of Immunology
Volume169
Issue number11
DOIs
Publication statusPublished - 2002 Dec 1

Fingerprint

Interleukin-13
Eosinophilia
Bronchoalveolar Lavage
Mucus
Aerosols
Allergens
Compliance
Immunoglobulin G
Inflammation
Lung
Injections
Proteins

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Taube, C., Duez, C., Cui, Z. H., Takeda, K., Rha, Y. H., Park, J., ... Gelfand, E. W. (2002). The role of IL-13 in established allergic airway disease. Journal of Immunology, 169(11), 6482-6489. https://doi.org/10.4049/jimmunol.169.11.6482
Taube, Christian ; Duez, Catherine ; Cui, Zhi Hua ; Takeda, Katsuyuki ; Rha, Yeong Ho ; Park, Jungwon ; Balhorn, Annette ; Donaldson, Debra D. ; Dakhama, Azzeddine ; Gelfand, Erwin W. / The role of IL-13 in established allergic airway disease. In: Journal of Immunology. 2002 ; Vol. 169, No. 11. pp. 6482-6489.
@article{ad2c98f3a75d4817a048adb995faa660,
title = "The role of IL-13 in established allergic airway disease",
abstract = "The effectiveness of targeting IL-13 in models where airway hyperresponsiveness (AHR) and airway inflammation have already been established is not well-described. We investigated the effects of blocking IL-13 on the early and late phase airway responses and the development of AHR in previously sensitized and challenged mice. BALB/cByJ mice were sensitized (days 1 and 14) and challenged (days 28-30) with OVA. Six weeks later (day 72), previously sensitized/challenged mice were challenged with a single OVA aerosol and the early and late phase response and development of AHR were determined. Specific in vivo blockade of IL-13 was attained after i.p. injection of a soluble IL-13Rα2-IgG fusion protein (sIL-13Rα2Fc) on days 71-72 for the early and late responses and on days 71-73 for the development of AHR. sIL-13Rα2Fc administration inhibited the late, but not early, phase response and the OVA challenge-induced changes in lung resistance and dynamic compliance; as well, sIL-13Rα2Fc administration decreased bronchoalveolar lavage eosinophilia and mucus hypersecretion following the secondary challenge protocols. These results demonstrate that targeting IL-13 alone regulates airway responses when administrated to mice with established allergic airway disease. These data identify the importance of IL-13 in the development of allergen-induced altered airway responsiveness following airway challenge, even when administered before rechallenge of mice in which allergic disease had been previously established.",
author = "Christian Taube and Catherine Duez and Cui, {Zhi Hua} and Katsuyuki Takeda and Rha, {Yeong Ho} and Jungwon Park and Annette Balhorn and Donaldson, {Debra D.} and Azzeddine Dakhama and Gelfand, {Erwin W.}",
year = "2002",
month = "12",
day = "1",
doi = "10.4049/jimmunol.169.11.6482",
language = "English",
volume = "169",
pages = "6482--6489",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

Taube, C, Duez, C, Cui, ZH, Takeda, K, Rha, YH, Park, J, Balhorn, A, Donaldson, DD, Dakhama, A & Gelfand, EW 2002, 'The role of IL-13 in established allergic airway disease', Journal of Immunology, vol. 169, no. 11, pp. 6482-6489. https://doi.org/10.4049/jimmunol.169.11.6482

The role of IL-13 in established allergic airway disease. / Taube, Christian; Duez, Catherine; Cui, Zhi Hua; Takeda, Katsuyuki; Rha, Yeong Ho; Park, Jungwon; Balhorn, Annette; Donaldson, Debra D.; Dakhama, Azzeddine; Gelfand, Erwin W.

In: Journal of Immunology, Vol. 169, No. 11, 01.12.2002, p. 6482-6489.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The role of IL-13 in established allergic airway disease

AU - Taube, Christian

AU - Duez, Catherine

AU - Cui, Zhi Hua

AU - Takeda, Katsuyuki

AU - Rha, Yeong Ho

AU - Park, Jungwon

AU - Balhorn, Annette

AU - Donaldson, Debra D.

AU - Dakhama, Azzeddine

AU - Gelfand, Erwin W.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - The effectiveness of targeting IL-13 in models where airway hyperresponsiveness (AHR) and airway inflammation have already been established is not well-described. We investigated the effects of blocking IL-13 on the early and late phase airway responses and the development of AHR in previously sensitized and challenged mice. BALB/cByJ mice were sensitized (days 1 and 14) and challenged (days 28-30) with OVA. Six weeks later (day 72), previously sensitized/challenged mice were challenged with a single OVA aerosol and the early and late phase response and development of AHR were determined. Specific in vivo blockade of IL-13 was attained after i.p. injection of a soluble IL-13Rα2-IgG fusion protein (sIL-13Rα2Fc) on days 71-72 for the early and late responses and on days 71-73 for the development of AHR. sIL-13Rα2Fc administration inhibited the late, but not early, phase response and the OVA challenge-induced changes in lung resistance and dynamic compliance; as well, sIL-13Rα2Fc administration decreased bronchoalveolar lavage eosinophilia and mucus hypersecretion following the secondary challenge protocols. These results demonstrate that targeting IL-13 alone regulates airway responses when administrated to mice with established allergic airway disease. These data identify the importance of IL-13 in the development of allergen-induced altered airway responsiveness following airway challenge, even when administered before rechallenge of mice in which allergic disease had been previously established.

AB - The effectiveness of targeting IL-13 in models where airway hyperresponsiveness (AHR) and airway inflammation have already been established is not well-described. We investigated the effects of blocking IL-13 on the early and late phase airway responses and the development of AHR in previously sensitized and challenged mice. BALB/cByJ mice were sensitized (days 1 and 14) and challenged (days 28-30) with OVA. Six weeks later (day 72), previously sensitized/challenged mice were challenged with a single OVA aerosol and the early and late phase response and development of AHR were determined. Specific in vivo blockade of IL-13 was attained after i.p. injection of a soluble IL-13Rα2-IgG fusion protein (sIL-13Rα2Fc) on days 71-72 for the early and late responses and on days 71-73 for the development of AHR. sIL-13Rα2Fc administration inhibited the late, but not early, phase response and the OVA challenge-induced changes in lung resistance and dynamic compliance; as well, sIL-13Rα2Fc administration decreased bronchoalveolar lavage eosinophilia and mucus hypersecretion following the secondary challenge protocols. These results demonstrate that targeting IL-13 alone regulates airway responses when administrated to mice with established allergic airway disease. These data identify the importance of IL-13 in the development of allergen-induced altered airway responsiveness following airway challenge, even when administered before rechallenge of mice in which allergic disease had been previously established.

UR - http://www.scopus.com/inward/record.url?scp=0036884608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036884608&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.169.11.6482

DO - 10.4049/jimmunol.169.11.6482

M3 - Article

VL - 169

SP - 6482

EP - 6489

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -